iRhythm Technologies to Participate in the Citi 2024 Global Healthcare Conference

11/20/24 4:30:00 PM ET

Medical/Dental Instruments

Health Care

Get the next $IRTC alert in real time by email

SAN FRANCISCO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will be participating in the upcoming Citi 2024 Global Healthcare Conference.

iRhythm's management is scheduled to participate in a fireside chat on Wednesday, December 4, 2024, at 10:15 am Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Events & Presentations" section of the company's investor website at investors.irhythmtech.com.

About iRhythm Technologies, Inc.

iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm's vision is to deliver better data, better insights, and better health for all.

Investor Contact

Stephanie Zhadkevich

[email protected]

Media Contact

Kassandra Perry

[email protected]

Get the next $IRTC alert in real time by email

Date	Price Target	Rating	Analyst
10/4/2024	$78.00	Neutral	Goldman
6/20/2024	$115.00	Peer Perform → Outperform	Wolfe Research
12/11/2023	$110.00	Neutral → Buy	Citigroup
7/19/2023	$130.00	Outperform	Robert W. Baird
2/7/2023	$150.00	Overweight	Wells Fargo
11/7/2022		Underperform → Peer Perform	Wolfe Research
6/9/2022	$180.00 → $155.00	Buy → Neutral	Citigroup
4/6/2022	$105.00	Underperform	Wolfe Research

iRhythm Technologies to Participate in the Citi 2024 Global Healthcare Conference

Chat with this insight

Recent Analyst Ratings for $IRTC

$IRTC Financials

Live finance-specific insights

iRhythm Technologies Announces Third Quarter 2024 Financial Results

iRhythm Technologies to Report Third Quarter 2024 Financial Results on October 30, 2024

iRhythm Technologies Announces Second Quarter 2024 Financial Results

$IRTC Press Releases

Fastest customizable press release news feed in the world

iRhythm Technologies to Participate in the Citi 2024 Global Healthcare Conference

iRhythm Data Presented at the American Heart Association 2024 Scientific Sessions Reinforce Clinical and Health Economic Value of Zio Long-Term Continuous Monitoring

iRhythm Technologies to Participate in the Wolfe Research 2024 Healthcare Conference

$IRTC SEC Filings

SEC Form 10-Q filed by iRhythm Technologies Inc.

iRhythm Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

iRhythm Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

$IRTC Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Talwalkar Abhijit Y bought $500,866 worth of shares (6,664 units at $75.16), increasing direct ownership by 54% to 18,941 units (SEC Form 4)

President and CEO Blackford Quentin S. was granted 280 shares and sold $1,249,784 worth of shares (16,145 units at $77.41), decreasing direct ownership by 9% to 159,929 units (SEC Form 4)

Chief Financial Officer Bobzien Brice sold $96,506 worth of shares (1,372 units at $70.34), decreasing direct ownership by 5% to 24,428 units (SEC Form 4)

$IRTC Market Insights

Live Market Insights

The Analyst Verdict: iRhythm Technologies In The Eyes Of 5 Experts

Truist Securities Maintains Buy on iRhythm Technologies, Lowers Price Target to $134

Morgan Stanley Maintains Overweight on iRhythm Technologies, Lowers Price Target to $130

$IRTC Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Goldman initiated coverage on iRhythm with a new price target

iRhythm upgraded by Wolfe Research with a new price target

iRhythm upgraded by Citigroup with a new price target

$IRTC Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

$IRTC Leadership Updates

Live Leadership Updates

$IRTC Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

iRhythm collaborates with Epic to streamline access to Zio® service and drive more seamless connectivity between clinicians and patients

Derrick Sung Joins Aerin Medical as Chief Financial Officer

iRhythm Technologies Further Strengthens its Board of Directors with Two New Independent Director Appointments

Director Talwalkar Abhijit Y bought $500,866 worth of shares (6,664 units at $75.16), increasing direct ownership by 54% to 18,941 units (SEC Form 4)

Chief Commercial Officer Patterson Chad bought $20,994 worth of shares (280 units at $74.98) and sold $224,876 worth of shares (3,012 units at $74.66), decreasing direct ownership by 7% to 37,133 units (SEC Form 4)

Blackford Quentin S. bought $997,644 worth of shares (9,755 units at $102.27), increasing direct ownership by 8% to 128,510 units (SEC Form 4) (Amendment)

Recent Analyst Ratings for
$IRTC

$IRTC
Financials

$IRTC
Press Releases

$IRTC
SEC Filings

$IRTC
Insider Trading

$IRTC
Market Insights

$IRTC
Analyst Ratings

$IRTC
Large Ownership Changes

$IRTC
Leadership Updates

$IRTC
Insider Purchases